Imbruvica (ibrutinib) - AbbVie, J&J
narazaciclib (HX301) - Traws Pharma
nemtabrutinib (MK-1026) - Merck (MSD)
Jaypirca (pirtobrutinib) - Eli Lilly
Calquence (acalabrutinib) - AstraZeneca
Kisqali (ribociclib) - Novartis
Ibrance (palbociclib) - Pfizer
Verzenio (abemaciclib) - Eli Lilly
Undisclosed CDK4/6 inhibitor - CS Group
https://library.ehaweb.org/eha/2024/eha2024-congress/419359/gal.rou.the.multikinase.cdk4.6.inhibitor.narazaciclib.overcomes.btk-i.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Ace_id%3D2552%2Aot_id%3D29172%2Amarker%3D5101%2Afeatured%3D18527
 
Nuria Profitos-Peleja; Jeronimo Parra; Marcelo Ribeiro; Miranda Fernandez-Serrano; Mireia Pellicer; Pau Marin-Escudero; Joan Josep Bech; Carolina De La Torre; Stephen Cosenza; Steven Fruchtman; Manel Esteller; Gaël Roué
 
May 15, 2024
 
Next